// App-Quantinova.ai

BSH2020‐PO‐003 : BCAT1 increases sensitivity to Cytarabine and confers CXXC motif derived resistance to pro‐oxidant treatment in Acute Myeloid Leukaemia cells

Researchers

Presenter

  • J. Hillier

Principal Investigators

  • W. Heaselgrave

  • S. Coles

Medical Centers

  • University of Worcester Worcester UK

  • University of Wolverhampton, Wolverhampton, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Solid malignancies

Biomarkers

  • Proto-oncogene tyrosine-protein kinase ROS

  • Exhaled breath hydrogen peroxide

  • L-serine

Drug/Treatment

  • Cytarabine liposomal

  • Cysteine Hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved